Cooperation of Oligodeoxynucleotides and Synthetic Molecules As Enhanced Immune Modulators

Overview

Journal Front Nutr

Specialty Nutritional Sciences

Date 2019 Sep 12

PMID 31508424

Citations 15

Authors

Shireen Nigar

Takeshi Shimosato

Affiliations

Soon will be listed here.

Abstract

Unmethylated cytosine-guanine dinucleotide (CpG) motifs are potent stimulators of the host immune response. Cellular recognition of CpG motifs occurs via Toll-like receptor 9 (TLR9), which normally activates immune responses to pathogen-associated molecular patterns (PAMPs) indicative of infection. Oligodeoxynucleotides (ODNs) containing unmethylated CpGs mimic the immunostimulatory activity of viral/microbial DNA. Synthetic ODNs harboring CpG motifs resembling those identified in viral/microbial DNA trigger an identical response, such that these immunomodulatory ODNs have therapeutic potential. CpG DNA has been investigated as an agent for the management of malignancy, asthma, allergy, and contagious diseases, and as an adjuvant in immunotherapy. In this review, we discuss the potential synergy between synthetic ODNs and other synthetic molecules and their immunomodulatory effects. We also summarize the different synthetic molecules that function as immune modulators and outline the phenomenon of TLR-mediated immune responses. We previously reported a novel synthetic ODN that acts synergistically with other synthetic molecules (including CpG ODNs, the synthetic triacylated lipopeptide PamCSK, lipopolysaccharide, and zymosan) that could serve as an immune therapy. Additionally, several clinical trials have evaluated the use of CpG ODNs with other immune factors such as granulocyte-macrophage colony-stimulating factor, cytokines, and both endosomal and cell-surface TLR ligands as adjuvants for the augmentation of vaccine activity. Furthermore, we discuss the structural recognition of ODNs by TLRs and the mechanism of functional modulation of TLRs in the context of the potential application of ODNs as wide-spectrum therapeutic agents.

Citing Articles

DNA vaccines as promising immuno-therapeutics against cancer: a new insight.

Shariati A, Khezrpour A, Shariati F, Afkhami H, Yarahmadi A, Alavimanesh S Front Immunol. 2025; 15:1498431.

PMID: 39872522 PMC: 11769820. DOI: 10.3389/fimmu.2024.1498431.

New insights for the development of efficient DNA vaccines.

Berger S, Zeyn Y, Wagner E, Bros M Microb Biotechnol. 2024; 17(11):e70053.

PMID: 39545748 PMC: 11565620. DOI: 10.1111/1751-7915.70053.

A novel immunomodulating peptide with potential to complement oligodeoxynucleotide-mediated adjuvanticity in vaccination strategies.

Agrez M, Chandler C, Thurecht K, Fletcher N, Liu F, Subramaniam G Sci Rep. 2024; 14(1):26737.

PMID: 39501043 PMC: 11538426. DOI: 10.1038/s41598-024-78150-7.

Effects of Synthetic Toll-Like Receptor 9 Ligand Molecules on Pulpal Immunomodulatory Response and Repair after Injuries.

Quispe-Salcedo A, Yamazaki T, Ohshima H Biomolecules. 2024; 14(8).

PMID: 39199319 PMC: 11353191. DOI: 10.3390/biom14080931.

Vaccine approaches to treat urothelial cancer.

Giudice G, Sonpavde G Hum Vaccin Immunother. 2024; 20(1):2379086.

PMID: 39043175 PMC: 11268260. DOI: 10.1080/21645515.2024.2379086.

References

Gans H, Maldonado Y, Yasukawa L, Beeler J, Audet S, Rinki M . IL-12, IFN-gamma, and T cell proliferation to measles in immunized infants. J Immunol. 1999; 162(9):5569-75. View

Deng G, Nilsson I, Verdrengh M, Collins L, Tarkowski A . Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis. Nat Med. 1999; 5(6):702-5. DOI: 10.1038/9554. View

Decker T, Schneller F, Sparwasser T, Tretter T, Lipford G, Wagner H . Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood. 2000; 95(3):999-1006. View

Behboudi S, Chao D, Klenerman P, Austyn J . The effects of DNA containing CpG motif on dendritic cells. Immunology. 2000; 99(3):361-6. PMC: 2327178. DOI: 10.1046/j.1365-2567.2000.00979.x. View

Akashi S, Shimazu R, Ogata H, Nagai Y, Takeda K, Kimoto M . Cutting edge: cell surface expression and lipopolysaccharide signaling via the toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages. J Immunol. 2000; 164(7):3471-5. DOI: 10.4049/jimmunol.164.7.3471. View

Yamamoto M, Yoshizaki K, Kishimoto T, Ito H . IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol. 2000; 164(9):4878-82. DOI: 10.4049/jimmunol.164.9.4878. View

Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S . Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med. 2000; 6(5):583-8. DOI: 10.1038/75068. View

Dagan R, Amir J, Mijalovsky A, Kalmanovitch I, Thoelen S, Safary A . Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr Infect Dis J. 2000; 19(11):1045-52. DOI: 10.1097/00006454-200011000-00004. View

Spellberg B, Edwards Jr J . Type 1/Type 2 immunity in infectious diseases. Clin Infect Dis. 2000; 32(1):76-102. DOI: 10.1086/317537. View

10.

Fehniger T, Caligiuri M . Interleukin 15: biology and relevance to human disease. Blood. 2001; 97(1):14-32. DOI: 10.1182/blood.v97.1.14. View

11.

Verthelyi D, Ishii K, Gursel M, Takeshita F, Klinman D . Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol. 2001; 166(4):2372-7. DOI: 10.4049/jimmunol.166.4.2372. View

12.

Sormunen H, Stenvik M, Eskola J, Hovi T . Age- and dose-interval-dependent antibody responses to inactivated poliovirus vaccine. J Med Virol. 2001; 63(4):305-10. DOI: 10.1002/1096-9071(200104)63:4<305::aid-jmv1006>3.0.co;2-u. View

13.

Bauer M, Redecke V, Ellwart J, Scherer B, Kremer J, Wagner H . Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells. J Immunol. 2001; 166(8):5000-7. DOI: 10.4049/jimmunol.166.8.5000. View

14.

Pisetsky D . Immune responses to DNA in normal and aberrant immunity. Immunol Res. 2001; 22(2-3):119-26. DOI: 10.1385/IR:22:2-3:119. View

15.

Mondal S, Naqi S . Maternal antibody to infectious bronchitis virus: its role in protection against infection and development of active immunity to vaccine. Vet Immunol Immunopathol. 2001; 79(1-2):31-40. PMC: 7119856. DOI: 10.1016/s0165-2427(01)00248-3. View

16.

Akira S, Takeda K, Kaisho T . Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001; 2(8):675-80. DOI: 10.1038/90609. View

17.

Kaisho T, Akira S . Toll-like receptors and their signaling mechanism in innate immunity. Acta Odontol Scand. 2001; 59(3):124-30. DOI: 10.1080/000163501750266701. View

18.

Gans H, Yasukawa L, Rinki M, DeHovitz R, Forghani B, Beeler J . Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis. 2001; 184(7):817-26. DOI: 10.1086/323346. View

19.

Takeda K, Akira S . Roles of Toll-like receptors in innate immune responses. Genes Cells. 2001; 6(9):733-42. DOI: 10.1046/j.1365-2443.2001.00458.x. View

20.

Takeshita F, Leifer C, Gursel I, Ishii K, Takeshita S, Gursel M . Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol. 2001; 167(7):3555-8. DOI: 10.4049/jimmunol.167.7.3555. View